The US Patent and Trademark Office (USPTO) has granted a patent to Vistagen’s non-opioid oral product candidate, AV-101 for ...

Objective: To assess the efficacy, safety and impact on quality of life of tramadol in the treatment of neuropathic pain in patients with cancer. Methods: Patients with similar characteristics ...

Navigation Menu Toggle navigation Sign in ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

A thorough assessment can lead to an accurate diagnosis and effective treatment plan. Pinched nerves are a cause of a type of ... and it is unknown why some individuals develop pain while others don't ...

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...

Medically reviewed by Amy Kwan, PT Your latissimus dorsi (your "lats") is a broad, flat, triangle-shaped muscle that spans ...

Changes in the brain with cortical reorganisation to gut stimulation and increased activity in specific electroencephalographic features characteristic for neuropathic pain are also seen in patients ...

(THE CONVERSATION) Chronic pain affects hundreds of millions of people around the world. But the opioid crisis in North America led many health care providers to realize they relied too heavily on ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Gabapentinoids are increasingly prescribed as an alternative to pain medicines for nursing home residents, but the reasoning behind the prescriptions — and beliefs about efficacy and deprescribing — ...